Ono Pharmaceutical (OTCMKTS:OPHLF) Shares Gap Down – Should You Sell?

Ono Pharmaceutical Co. (OTCMKTS:OPHLF)’s share price gapped down prior to trading on Monday. The stock had previously closed at $16.11, but opened at $13.6650. Ono Pharmaceutical shares last traded at $13.6650, with a volume of 686 shares.

Analyst Upgrades and Downgrades

Separately, Zacks Research cut shares of Ono Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research report on Friday, September 4th. One investment analyst has rated the stock with a Hold rating, According to data from MarketBeat.com, Ono Pharmaceutical currently has a consensus rating of “Hold”.

Ono Pharmaceutical Stock Performance

The stock has a market cap of $7.19 billion, a P/E ratio of 14.57 and a beta of 0.33. The business has a 50 day moving average price of $14.97 and a 200 day moving average price of $14.61. The company has a quick ratio of 2.86, a current ratio of 3.28 and a debt-to-equity ratio of 0.08.

About Ono Pharmaceutical

Ono Pharmaceutical Co, Ltd. is a Japanese research-driven pharmaceutical company headquartered in Osaka. The company discovers, develops, manufactures and markets prescription medicines, with a focus on oncology, immunology, neurology and other specialty-care areas. Its activities include both internally developed products and collaborations with pharmaceutical and biotechnology companies worldwide.

Ono is best known internationally for Opdivo (nivolumab), an immune checkpoint inhibitor developed in collaboration with Bristol Myers Squibb and used to treat multiple types of cancer.